FisherBroyles partner Xiaoban Xin examines the evolving legal landscape for patenting antibody-drug conjugate (ADC) inventions in a new Law360 article, “Key Tips For Patenting Antibody-Drug Conjugate Inventions.”
Jul 6, 2026
As ADC innovation continues to accelerate, recent Federal Circuit and Supreme Court decisions have reshaped the standards for written description and enablement. Xiaoban provides practical guidance for drafting stronger patent applications and developing effective IP strategies for these complex biologic technologies.
Read the full article here. (subscription required)
About FisherBroyles, LLP
Founded in 2002, FisherBroyles, LLP is the first and one of the world’s largest distributed law firm partnerships. The Next Generation Law Firm® has grown to hundreds of partners practicing in 32 markets globally. The FisherBroyles’ efficient and cost-effective Law Firm 2.0® model leverages talent and technology instead of unnecessary overhead that does not add value to our clients, all without sacrificing BigLaw quality. Visit our website at www.fisherbroyles.com to learn more about our firm’s unique approach and how we can best meet your legal needs.
These materials have been prepared for informational purposes only, do not constitute legal advice, and under applicable rules of professional conduct governing attorneys in various jurisdictions, may be considered advertising materials. This information is not intended to and does not create an attorney-client or similar relationship. Whether you need legal services and which lawyer you select are important decisions that should not be based on these materials and information alone.
© 2026 FisherBroyles, LLP